Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) shares gapped up before the market opened on Thursday . The stock had previously closed at $13.51, but opened at $15.19. Pharming Group shares last traded at $14.91, with a volume of 892 shares.
Pharming Group Price Performance
The company's 50-day moving average is $12.15 and its two-hundred day moving average is $10.42. The firm has a market cap of $986.89 million, a P/E ratio of -110.82 and a beta of 0.05. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.79 and a quick ratio of 2.07.
Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.16. The business had revenue of $93.20 million during the quarter, compared to analyst estimates of $70.36 million. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. Pharming Group has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current fiscal year.
Institutional Trading of Pharming Group
A hedge fund recently bought a new stake in Pharming Group stock. EverSource Wealth Advisors LLC bought a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,979 shares of the company's stock, valued at approximately $32,000. 0.03% of the stock is owned by hedge funds and other institutional investors.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
See Also
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
